<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03304899</url>
  </required_header>
  <id_info>
    <org_study_id>Isfahan University</org_study_id>
    <nct_id>NCT03304899</nct_id>
  </id_info>
  <brief_title>Fibrinogen Concentrate in Isolated Traumatic Brain Injury</brief_title>
  <official_title>Early Fibrinogen Concentrate in Isolated Traumatic Brain Injury and the Effect on Post Bleeding &amp; Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leila Dehghani</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Isfahan University of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fibrinogen is a unique precursor of fibrin and cannot be compensated for by other coagulation
      factors. If plasma fibrinogen concentrations are insufficient, hemostatic clots cannot be
      formed with the appropriate firmness. In severe traumatic brain injury(TBI) patients, plasma
      fibrinogen concentrations decrease earlier and more frequently than other coagulation
      factors,predicting massive bleeding and death.

      The purpose of this study is to try early injection of fibrinogen concentrate in severe
      isolated traumatic brain injury and investigation the effect of it on post bleeding and
      complications.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 23, 2017</start_date>
  <completion_date type="Anticipated">January 21, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 21, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality rate.</measure>
    <time_frame>Until 90 days after admission.</time_frame>
    <description>Mortality rate after injection of fibrinogen concentrate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average of serum fibrinogen level.</measure>
    <time_frame>Immediately after admission.</time_frame>
    <description>Average of serum fibrinogen level in iTBI patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of early fibrinogen on post trauma bleeding (Intracranial hemorrhage).</measure>
    <time_frame>2, 6, 24, 72 hours and 30 , 90 days after admission.</time_frame>
    <description>The need to packed cell, FFP, Platelete.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The complications that related to fibrinogen concentrate.</measure>
    <time_frame>until 90 days after admission.</time_frame>
    <description>like DVT, PTE, MI.by measurement of serum D-dimer for DVT and PTE and serum Troponin C for MI.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe isolated Traumatic Brain injury patients with serum fibrinogen level under 200 mg/dl that receive Fibrinogen concentrate after common emergency resuscitation. Instruction:
Airway control &amp; breathing.
Circulation (Serum therapy, Epinephrine,Packed cell, FFP and ...).
Fibrinogen Concentrate(IV injection): Each vial contains 1gr fibrinogen concentrate. Fibrinogen concentrate will be given until serum fibrinogen level riches to 200 mg/dl.
Dose (mg/kg body weight) = ([Target level (mg/dL) - measured level (mg/dL)])/(1.7 (mg/dL per mg/kg body weight))</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Severe isolated Traumatic Brain injury patients with serum fibrinogen level under 200 mg/dl that receive common emergency resuscitation. Instruction:
Airway control &amp; breathing.
Circulation (Serum therapy, Epinephrine,Packed cell, FFP and ...).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RiaSTAP Injectable Product</intervention_name>
    <description>RiaSTAP, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes.
Dose (mg/kg body weight) =
([Target level (mg/dL) - measured level (mg/dL)])/(1.7 (mg/dL per mg/kg body weight))</description>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with severe isolated traumatic brain injury.

        Exclusion Criteria:

          -  Severe abdomen or extremities trauma.

          -  Severe bleeding from abdomen or extremities.

          -  Congenital coagulopathy (Hemophilia, protein S and C deficiency, Factor 5 Leiden
             deficiency and ...).

          -  Warfarin, Heparin, Enoxaparin, Dabigatran and other anticoagulation drugs consumption.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mahdi Vahidian, Student</last_name>
    <phone>+989103374626</phone>
    <email>Mehdivahid2@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Isfahan university of medical science.</name>
      <address>
        <city>Isfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahdi Vahidian, student</last_name>
      <phone>+989103374626</phone>
      <email>Mehdivahid2@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2017</study_first_submitted>
  <study_first_submitted_qc>October 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2017</study_first_posted>
  <last_update_submitted>October 6, 2017</last_update_submitted>
  <last_update_submitted_qc>October 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Isfahan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Leila Dehghani</investigator_full_name>
    <investigator_title>Early fibrinogen concentrate in severe isolated traumatic brain injury and the effect on post bleeding and complications.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

